Valion Bio VBIO 深 滬
等待開盤 09-23 09:30:00 美东时间
2.49
+0.110
+4.62%
華盛通- 最 高2.80
- 今 開2.41
- 成交量 54.01万股
- 最 低 2.3601
- 昨 收 2.38
- 總市值 320.12万
- 52周最高 78.75
- 市盈率 靜 --
- 換手率 42.01%
- 52周最低 2.05
- 委 比 4.76%
- 總股本 128.56万
- 歷史最高 276250.00
- 量 比 4.91
- 振 幅 18.48%
- 歷史最低 2.3601
- 每 手 1
- 風險率 21.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Valion Bio Appoints Lisa Wolf To Expanded Roles Of President, COO, Effective Immediately
Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company, today announced strategic changes to its management team and Board of Directors designed to accelerate execution across its clinical and commercial initiatives and position the Company for its nex...
09-01 20:09
Valion Bio raises capital via new preferred financing
The latest update is out from Valion Bio ( ($VBIO) ). On August 31, 2026, Valio...
09-01 18:29
Valion Bio Announces 1-For-25 Reverse Stock Split, Effective Aug. 31
Valion Bio, Inc. (Nasdaq:VBIO) ("Valion Bio" or the "Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock split of the Company's issued and outstanding shares of common stock. The purpose of the reverse stock split is to bring the Company into compliance with th...
08-27 20:32
Why Cadeler Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Shares of Cadeler A/S – ADR (NYSE:CDLR) rose sharply in pre-market trading after the company reported interim financial results for the first half of 2026. Revenue for the first six months of 2026 jumped to EUR 408 million from EUR 188 million in the year-ago period. Profit for the period climbed 54...
08-25 17:25
Why Cadeler Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Shares of Cadeler A/S – ADR (NYSE:CDLR) rose sharply in pre-market trading after the company reported interim financial results for the first half of 2026. Revenue for the first six months of 2026 jumped to EUR 408 million from EUR 188 million in the year-ago period. Profit for the period climbed 54...
08-25 17:25
Valion Bio To Carry Out Study At Sheba Medical Center To Mull Entolimod In 10 Cancer Participants
Valion Bio, Inc. (NASDAQ:VBIO) today announced a major clinical development milestone with the finalization of an clinical trial protocol at Sheba Medical Center, one of the world's leading hospitals, to evaluate Entolimod in cancer patients receiving high doses of irradiation for a rare form of can...
07-21 01:35
Valion Bio Q1 2026 Earnings Call: Complete Transcript
On Thursday, Valion Bio (NASDAQ:VBIO) discussed first-quarter financial results...
05-15 05:20
Valion Bio's Velocity Bioworks Enters Into Exclusive Commercial Development And License Agreement With LarmorBio For BioScan-NMR Platform
First Commercial Installation Targeted for July 2026 in San Antonio; Strategic Reference Site Positions Velocity Bioworks at the Forefront of Next-Generation NMR-Based DiagnosticsSAN ANTONIO, May 14, 2026 /PRNewswire/ --
05-15 04:34
Valion Bio Q1 EPS $(2.23) Up From $(2.52) YoY
Valion Bio (NASDAQ:VBIO) reported quarterly losses of $(2.23) per share. This is a 11.51 percent increase over losses of $(2.52) per share from the same period last year.
05-15 04:08
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
